ImmuneRegen Biosciences

News

ImmuneRegen News

USAFSAM Initiates Notice of ImmuneRegen's Compound for Possible Use in Anthrax Exposure

ImmuneRegen Begins Anthrax Treatment Study

SCOTTSDALE, Ariz., Oct. 20, 2005 -- ImmuneRegen BioSciences, a wholly owned subsidiary of IR BioSciences Holdings, Inc. (BULLETIN BOARD: IRBO), today announced that it will be working closely with Hyperion Biotechnology Inc. in new tests of Viprovex™, the proprietary compound which has been found to reverse lung damage and stimulate suppressed or failing immune systems, as a treatment to the anthrax infection. The purpose of the test is to see if the immune-stimulant will reduce the mortality rate of an active infection of pulmonary anthrax. These tests will also look for the efficacy of Viprovex™ as a preventative to pulmonary anthrax sickness. The test will be conducted at Brooks City-Base in San Antonio, Texas with the cooperation of the U.S. Air Force School of Aerospace Medicine (USAFSAM).

“Even the inhalation of very small numbers of anthrax spores can be deadly because once the spores mature in the lungs, they start producing toxins that destroy the body's ability to combat the infection,” Says Michael Wilhelm, co-founder and CEO of ImmuneRegen. “Our past research suggests that Viprovex™ plays an important role during early responses of the lungs to a variety of substances. We have already found that Viprovex™ blocks the inflammatory cascade that leads to the destruction of lung tissue. Based on this, our hypothesis for this round of testing is that Viprovex™ will have a similar effect combating anthrax spores.”

The tests will be conducted by Hyperion Biotechnology Inc. Hyperion’s research facility is located on the Air Force School of Aerospace Medicine (USAFSAM) campus in Brooks City- Base, TX.

Viprovex™, derived from ImmuneRegen’s modified Substance P compound Homspera™, is a treatment currently in development for infectious diseases and biological warfare agents. Viprovex™ has shown efficacy in treating Acute Respiratory Distress Syndrome (ARDS), Hong Kong Influenza, and other toxic conditions involving jet diesel fuel. During early research, Dr. Mark L. Witten, co-founder of ImmuneRegen BioSciences, and his associates observed that exposure to jet fuels depleted endogenous pulmonary Substance P levels and resulted in pathological changes in the lungs and immune system. It was also observed that the administration of exogenous Substance P seemed to protect the lungs, as well as stimulate the immune system.

About ImmuneRegen BioSciences, Inc.
ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. (BULLETIN BOARD: IRBO), is a biotechnology company engaged in the research and development of applications utilizing modified Substance P, a naturally occurring immunomodulator. Derived from homeostatic substance P, the company has named their proprietary compound "Homspera." The Company's initial focus is on the continuing development of Homspera for various applications for use in improving pulmonary function and stimulating the human immune system. For more information, please visit the company's website at www.immuneregen.com.

About ImmuneRegen BioSciences, Inc.

a wholly owned subsidiary of IR BioSciences Holdings, Inc., (OTC BB:IRBS.OB - News) is a development-stage biotechnology company focused on the research, development and licensing of Homspera™ and its derivatives. Homspera is an adult stem cell active compound that in study results has been shown to regenerate and strengthen the immune system and enhance wound healing. Viprovex®, a derivative of Homspera, is being developed for potential use against infectious diseases as a stand-alone or combination therapy and as a vaccine adjuvant. To advance its mission, the Scottsdale, Arizona based company has forged numerous study partnerships with industry and academic leaders, including Celgene Cellular Therapeutics, HemoGenix, Lovelace Respiratory Research Institute and Virion Systems. For more information, please visit www.immuneregen.com.

Statements about ImmuneRegen's future expectations, including statements about the potential use and scientific results for ImmuneRegen's drug candidates, science and technology, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. ImmuneRegen intends that such forward-looking statements be subject to the safe harbors created thereby. These future events may not occur as and when expected, if at all, and, together with ImmuneRegen's business, are subject to various risks and uncertainties. ImmuneRegen's actual results could differ materially from expected results as a result of a number of factors, including the uncertainties inherent in research and development collaborations, pre-clinical and clinical trials and product development programs (including, but not limited to the fact that future results or research and development efforts may prove less encouraging than current results or cause side effects not observed in current pre-clinical trials), the evaluation of potential opportunities, the level of corporate expenditures and monies available for further studies, capital market conditions, and others set forth in ImmuneRegen's periodic report on Form 10-Q for the three months ended June 30, 2008 and on Form 10-KSB for the year ended December 31, 2007 as filed with the Securities and Exchange Commission. There are no guarantees that any of ImmuneRegen's proposed products will prove to be commercially successful. ImmuneRegen undertakes no duty to update forward-looking statements.

Contact:
Amendola Communications for ImmuneRegen
Jan Shulman, 480-664-8412 ext. 12
jshulman@ACmarketingPR.com

Jodi Amendola, 480-664-8412 ext 11
jamendola@ACmarketingPR.com

###